Hospital Universitario Araba-ko ikertzaileekin lankidetzan egindako argitalpenak (21)

2024

  1. Evaluation of Genetic Variants Associated with the Risk of Thiopurine-Related Pancreatitis: A Case Control Study from ENEIDA Registry

    Digestive Diseases, Vol. 42, Núm. 3, pp. 257-264

  2. Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registry

    Alimentary Pharmacology and Therapeutics, Vol. 60, Núm. 5, pp. 604-612

  3. Sex-Related Differences in the Phenotype and Course of Inflammatory Bowel Disease: SEXEII Study of ENEIDA

    Clinical Gastroenterology and Hepatology, Vol. 22, Núm. 11, pp. 2280-2290

  4. Transmural cross-sectional findings and bowel damage assessment in preclinical Crohn’s disease: a case-control study

    International Journal of Colorectal Disease, Vol. 39, Núm. 1

2023

  1. Long-Term Outcomes of Biological Therapy in Crohn's Disease Complicated with Internal Fistulizing Disease: BIOSCOPE Study from GETECCU

    American Journal of Gastroenterology, Vol. 118, Núm. 6, pp. 1036-1046

  2. Subclinical bowel inflammation increases healthcare resources utilization and steroid use before diagnosis of inflammatory bowel disease

    United European Gastroenterology Journal, Vol. 11, Núm. 1, pp. 9-18

2022

  1. Management and Long-term Outcomes of Crohn's Disease Complicated with Enterocutaneous Fistula: ECUFIT Study from GETECCU

    Journal of Crohn's & colitis, Vol. 16, Núm. 7, pp. 1049-1058

  2. Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)

    Journal of Clinical Medicine, Vol. 11, Núm. 24

2021

  1. A Novel Noninvasive Method Based on Salivary Inflammatory Biomarkers for the Screening of Celiac Disease

    Cellular and Molecular Gastroenterology and Hepatology

2020

  1. Characteristics and Prognosis of Patients With Inflammatory Bowel Disease During the SARS-CoV-2 Pandemic in the Basque Country (Spain)

    Gastroenterology, Vol. 159, Núm. 2, pp. 781-783

  2. Early microscopic findings in preclinical inflammatory bowel disease

    Digestive and Liver Disease, Vol. 52, Núm. 12, pp. 1467-1472

  3. Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients with Inflammatory Bowel Disease: Results from the Eneida Registry

    Inflammatory Bowel Diseases, Vol. 26, Núm. 4, pp. 606-616

2018

  1. Adalimumab treatment of anti-TNF-naïve patients with ulcerative colitis: Deep remission and response factors

    Digestive and Liver Disease, Vol. 50, Núm. 8, pp. 812-819

  2. Author’s reply: “A question on dyspeptic patients analyzed by psychometric scores”

    Revista Espanola de Enfermedades Digestivas

  3. Characteristics and Progression of Preclinical Inflammatory Bowel Disease

    Clinical Gastroenterology and Hepatology, Vol. 16, Núm. 9, pp. 1459-1466

  4. New psychometric data from the Spanish versions of the glasgow dyspepsia severity score and the dyspepsia-related health scale measures

    Revista Espanola de Enfermedades Digestivas, Vol. 110, Núm. 1, pp. 10-18

2009

  1. Association between Mycobacterium avium subsp. paratuberculosis DNA in blood and cellular and humoral immune response in inflammatory bowel disease patients and controls

    International Journal of Infectious Diseases, Vol. 13, Núm. 2, pp. 247-254

2008

  1. On the prevalence of M. avium subspecies paratuberculosis DNA in the blood of healthy individuals and patients with inflammatory bowel disease

    PLoS ONE, Vol. 3, Núm. 7

2004

  1. Erratum: Quality-of-life outcomes with laparoscopic vs open cholecystectomy (Surgical Endoscopy (2003) 17 (1129-1134) DOI: 10.1007/s00464-002-9202-2)

    Surgical Endoscopy and Other Interventional Techniques

2003

  1. Quality-of-life outcomes with laparoscopic vs open cholecystectomy

    Surgical Endoscopy, Vol. 17, Núm. 7, pp. 1118-1124